Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guangxi Shuangyi Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the development and production of Traditional Chinese Medicine (TCM) and chemical pharmaceuticals. The company is widely recognized for its Double Ant brand, specializing in ant-based therapeutic products designed to treat rheumatism and bone diseases. Its flagship product, Shuangyi Fufang Yigan Granules, is a leading treatment in the Chinese market for rheumatoid conditions. Headquartered in Laibin, Guangxi, the company maintains modern GMP-certified production lines for various dosage forms including tablets, capsules, and granules. Shuangyi Pharmaceutical emphasizes the modernization of traditional ethnic medicines to serve both the domestic OTC and prescription markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guangxi Shuangyi Pharmaceutical.